StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Enhertu (trastuzumab deruxtecan by Quarter

Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Enhertu (trastuzumab deruxtecan: $47M in Q2 2026, up 104.3% from a year earlier. That is the highest of the 22 quarters on record here.

Latest, Q2 2026
47
Period ended Jun 30, 2026
Change on a year earlier
+104.3%
23 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
22
Documents cited below

Where the Q2 2026 figure comes from

“|| Enhertu | | 338 | | 47 | | 44 | | - | | - | | 223 | | 43 | | 41 | | 68 | | 34 | | 28 | | 47 | | n/m | | 98”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEnhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202647+104.3%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202644+131.6%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202538+72.7%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202521+31.3%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202523+21.1%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202519+46.2%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202422+46.7%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202416+77.8%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202419+280.0%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202413+333.3%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202315+400.0%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20239+350.0%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20235+150.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 20233+200.0%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 20223–Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 20222–Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Enhertu (trastuzumab deruxtecan ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-enhertu-erow

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.